All Drug Discovery articles – Page 27
-
ArticleDrug Discovery Article Competition Winner
We are thrilled to announce the winner of the Drug Target Review x ELRIG's Article Competition: Dr Rosa Woldegebriel, Lead Scientist at the Human Centric Drug Discovery in Oxford, UK, whose article titled "Advancing Drug Discovery for Pain Disorders: Human iPSC-Based Approach" presents a revolutionary method in pharmaceutical research. ...
-
ArticleWomen in Stem with Theonie Anastassiadis
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Theonie Anastassiadis, Cofounder & Chief Innovation Officer of Alltrna and Senior Principal of Flagship Pioneering. As a senior principal at Flagship Pioneering, Theonie conceives, ...
-
ArticleTherapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
-
WebinarTurning Plans into Reality: Real Examples of Custom Automation Projects
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
-
ArticleHuntington's disease and potential therapies
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
-
NewsBreakthrough treatment defeats deadly fungus
Researchers at the RIKEN Center for Sustainable Research Science (CSRS) and the University of Toronto have discovered a method to combat fungal infections by targeting their fatty acid production.
-
NewsConversations about the NHS: a bold prescription for it’s future
As the NHS celebrates its 75th anniversary, healthcare leaders, policymakers, and practitioners have been sharing their innovative ideas on how to reshape and safeguard its future.
-
NewsCracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
-
ArticlePrecision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
-
ReportBeyond the lab: cell & gene therapy
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
-
ArticleGenetic variant identification: unveiling the power of STING-seq
In an exclusive interview, Dr Neville Sanjana, Associate Professor of biology at NYU and a core faculty member at the New York Genome Center, discusses the breakthrough study on STING-seq.
-
ArticleMalaria unravelled: decoding the parasite's gene expression control
Researchers from Tokyo Tech's World Research Hub Initiative conducted a study to investigate the regulation of gene expression in the apicoplast of the malaria parasite Plasmodium falciparum.
-
WebinarFunctional assays for the development of agonistic antibodies
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
-
ArticleCondensate biology: advancing drug discovery for complex diseases
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal ...
-
ArticleBiochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
-
ArticleThe future of central nervous system research
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain ...
-
ArticleEpigenetic editing: the next generation of genetic medicine
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
-
ArticleExploring alternatives to animal testing in drug discovery
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
-
ArticleTargeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation, ...
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.